Technology Review: AI Applications in Cell and Gene Therapy Manufacturing

25 February 2021

Edition two of Phacilitate’s technology review series examines the range of artificial intelligence, data management and analytics software to improve efficiencies in cell and gene therapy manufacturing. In partnership with Anemocyte.

In the context of advanced therapies bioprocessing, well-applied AI and ML can provide much needed competitive advantages, along with significant efficiency savings, improved batch release and, ultimately, the reduction of COGs. All of which contribute to getting treatments to more patients, more affordably and faster. However, neither AI nor solid data management are being mastered widely in our industry due to a number of factors including lack of expertise, a lack of fit-for-purpose technology and software along with a reluctance to invest and disrupt.

 This report showcases some of the leading and specialist software providers that can assist cell and gene therapy developers and manufacturers to collect, manage and analyse the right data, as well as developing AI and ML algorithms. For each organisation, there is a short overview of its services along with some perceived advantages and disadvantages of the service or software they provide. The table below provides a summary of the organisations in this report and has divided them into categories by function.

View the report

While it’s not an exhaustive list, we have included 12 organisations who either provide services and/or software specifically for life sciences and advanced therapies, or who provide multiple services and have the internal expertise smaller biotechs may lack.

  • Aglaris
  • Amazon Web Services
  • Asimov
  • Autolomus
  • Benchling
  • BigFinite
  • Bio-G (Emerson)
  • Exputec
  • Sartorius Stedim
  • Skyland Analytics
  • Synthace